Drugs / PRM-125
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05195827 | Dec 2021 → Sep 2022 | essential hypertension | PRM Pharma, LLC | Withdrawn | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRM-125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05195827 ↗ |